.

Dr Dan Rathbone

 

Senior Lecturer in Pharmaceutical Sciences

PG Programme Director - MSc Drug Design and MSc Molecular Pharmaceutics


School of Life & Health Sciences
Aston University

Aston Triangle
Birmingham B4 7ET
UK

telephone: +44 (0) 121 204 4002
fax: +44 (0) 121 359 0733

rathbodl-1.jpg
Dan Rathbone

Research Theme

Cellular and Molecular Biomedicine 

Research Centre

Aston Research Centre for Healthy Ageing (ARCHA) 

Teaching Activity on the MPharm Programme

PH1405: Heterocyclic chemistry
PH1408: IT training
PH3602: Various drug/disease lectures
PH3605: Drug and analysis, QSAR, combinatorial chemistry

Career History

2007 to date  Senior Lecturer, Aston University
1999-2007 Lecturer in Pharmaceutical Sciences, Aston University
1996-99 Research Fellow, Aston University
1990-95 Senior Chemist, Aston Molecules Ltd
1989 Postdoctoral Fellow, Warwick University
1988 Postdoctoral Fellow, Institut fur Organische Chemie und Biochemie, Bonn
1984-87 PhD, University of Warwick
1980-84 BA, Chemistry, St. Edmund Hall, University of Oxford

Research Interests

  • Design, synthesis and screening of libraries of new antimycobacterial compounds
  • Computer aided drug design
  • Molecular recognition in fluorescent imprinted polymers and their use as sensors and receptor mimics
  • Design and synthesis of transglutaminase inhibitors

Teaching Interests

  • MPharm course - medicinal chemistry and drug design
  • MSc Drug Design (programme director) – computer-aided drug design
  • MSc Molecular Pharmaceutics (programme director) - computer-aided drug design

Publications

  • Hay DL, Harris PW, Kowalczyk R, Brimble MA, Rathbone DL, Barwell J, Conner AC, Poyner DR (2013)
    Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation.
    British Journal of Pharmacology  doi: 10.1111/bph.12464
  • Badarau, E., Mongeot, A., Collighan, R., Rathbone, D. & Griffin, M. (2013)
    Imidazolium-based warheads strongly influence activity of water-soluble peptidic transglutaminase inhibitors
    European Journal of Medicinal Chemistry, 66; 526-530 (DOI: 10.1016/j.ejmech.2013.05.018)
  • Watkins, H. A., Rathbone, D. L., Barwell, J., Hay, D. L. & Poyner, D. R.(2013)
    Structure-activity relationships for alpha calcitonin gene-related peptide
    British Journal of Pharmacology - Accepted
  • Nooshin Daneshpour, Russell Collighan, Yvonne Perrie, Peter Lambert, Dan Rathbone, Deborah Lowry, Martin Griffin (2013)
    Indwelling catheters and medical implants with FXIIIa inhibitors: A novel approach to the treatment of catheter and medical device-related infections
    Eur. J. Pharmaceutics and Biopharmaceutics, 83: 106–113 (DOI:10.1016/j.ejpb.2012.09.005)
  • Wang Z, Collighan RJ, Pytel K, Rathbone DL, Li X, Griffin M. (2012)
    Characterization of Heparin-binding Site of Tissue Transglutaminase: ITS IMPORTANCE IN CELL SURFACE TARGETING, MATRIX DEPOSITION, AND CELL SIGNALING.
    J. Biol. Chem. 287: 13063-13083 (doi:10.1074/jbc.M111.294819)
  • Richard J. Bailey, Joshua W.I. Bradley, David R. Poyner, Dan L. Rathbone, Debbie L. Hay (2010)
    Functional characterization of two human receptor activity-modifying protein 3 variants
    Peptides, 31, 579–584 (DOI:10.1016/j.peptides.2009.12.016)
  • Tao Qi, John Simms, Richard J. Bailey, Mark Wheatley, Dan L. Rathbone, Debbie L. Hay and David R. Poyner (2010)
    Structure-Function Analysis of RAMP1-RAMP3 Chimeras
    Biochemistry, 49, 522–531 (DOI: 10.1021/bi9019093)
  • Martin Griffin, Alexandre Mongeot, Russell Collighan, Robert E. Saint, Richard A. Jones, Ian G.C. Coutts, Daniel L. Rathbone (2008)
    Synthesis of potent water-soluble tissue transglutaminase inhibitors
    Bioorg. Med. Chem. Lett., 18, 5559–5562
  • Cait Costello, Tarja Karpanen, Peter A. Lambert, Preena Mistry, Katy J. Parker, Daniel L. Rathbone, Jiangmeng Ren, Laura Wheeldon and Tony Worthington (2008)
    Thiosemicarbazones active against Clostridium difficile
    Bioorg. Med. Chem. Lett., 18, 1708–1711
  • Daniel L. Rathbone, Katy J. Parker, Michael D. Coleman, Peter A. Lambert and David C. Billington (2006)
    Discovery of a potent phenolic N1-benzylidene-pyridinecarboxamidrazone selective against Gram-positive bacteria
    Bioorg. Med. Chem. Lett., 16, 879-883
  • M.D. Coleman, R. Aerry, E. Wanogho, N.B. Khan, P.A. Lambert and D.L. Rathbone (2006)
    Effects of GSH and NAC on the antimicrobial efficacy of INH on M. fortuitum in vitro.
    J. Chemother. 18, 665-666
  • Daniel L. Rathbone (2005)
    Molecularly imprinted polymers in the drug discovery process
    Advanced Drug Delivery Reviews, 57, 1855-1875
  • Daniel L. Rathbone, Aisha Ali, Polyxeni Antonaki, Sarah Cheek (2005)
    Towards a polymeric binding mimic for cytochrome CYP2D6
    Biosensors and Bioelectronics, 20, 2353-2363
  • Daniel L. Rathbone and Ajeet Bains (2005)
    Tools for fluorescent molecularly imprinted polymers
    Biosensors and Bioelectronics, 20, 1438-1442
  • Michael D. Coleman, Nazish Khan, Graham Welton, Peter A. Lambert, Katy J. Tims and Daniel L. Rathbone (2004)
    Effects of glutathione, N-acetyl-cysteine, α-lipoic acid and dihydrolipoic acid on the cytotoxicity of a 2-pyridylcarboxamidrazone antimycobacterial agent in human mononuclear leucocytes in vitro
    Environ. Tox. Pharmacol., 17, 143-148
  • Simpson, J., Forrester, R., Tisdale, M.J., Billington, D.C. and Rathbone, D.L. (2003)
    Effect of Catechol Derivatives on Cell Growth and Lipoxygenase Activity
    Bioorg. Med. Chem. Lett., 13, 2435-2439
  • Coleman, M.D., Tims, K.J. and Rathbone, D.L., (2003)
    The use of computational QSAR analysis in the toxicological evaluation of a series of 2-pyridylcarboxamidrazone candidate anti-tuberculosis compounds.
    Environ. Tox. Pharmacol.
    , 14, 33-42
  • Gokhale, N.H.,� Padhye, S.B., Billington, D.C., Rathbone, D.L., Croft, S.L., Kendrick, H.D., Anson, C.E. and Powell, A.K. (2003)
    Synthesis and characterization of copper(II) complexes of pyridine-2-carboxamidrazones as potent antimalarial agents.
    Inorganica Chimica Acta
    , 349C, 23-29
  • Thanh, N.T.K., Rathbone, D.L., Billington, D.C. and Hartell, N.A. (2002)
    Selective Recognition Of Cyclic GMP Using A Fluorescence-Based Molecularly Imprinted Polymer.
    Analytical Letters
    , 35, 2499-2509
  • Sandbhor, U., Padhye, S., Billington, D.C.B., Rathbone, D.L., Franzblau, S., Anson, C.E. and Powell, A.K. (2002)
    Metal complexes of carboxamidrazone analogs as antitubercular agents 1. Synthesis, X-ray crystal-structures, spectroscopic properties and antimycobacterial activity against Mycobacterium tuberculosis H Rv 37.
    Journal of Inorganic Biochemistry
    , 90, 127-136
  • Rathbone, D.L. and Ge, Y. (2001)
    Selectivity of Response in Fluorescent Polymers Imprinted with N1 -Benzylidene Pyridine-2-Carboxamidrazones.
    Analytica Chimica Acta
    , 435, 129-136
  • Coleman, M.D., Rathbone, D.L., Chima, R., Lambert, P.A. and Billington, D.C. (2001)
    Preliminary In Vitro Toxicological Evaluation of A Series of 2-Pyridylcarboxamidrazone Candidate Anti-Tuberculosis Compounds III.
    Environ. Tox. Pharmacol.
    , 9, 99-102
  • Gokhale, N., Padhye, S., Rathbone, D.L., Billington, D., Lowe, P., Schwalbe, C. and Newton, C. (2001)
    The crystal structure of first copper(II) complex of a pyridine-2-carboxamidrazone - a potential antitumor agent.
    Inorg. Chem. Commun
    ., 4, 26-29
  • Coleman, M.D., Rathbone, D.L., Abberley, L., Lambert, P.A. and Billington, D.C. (2000)
    Preliminary In Vitro Toxicological Evaluation Of A Series Of 2-Pyridylcarboxamidrazone Candidate Anti-Tuberculosis Compounds II.
    Environ. Tox. Pharmacol
    ., 8, 167-172
  • Billington, D.C., Lowe, P.R., Rathbone, D.L., and Schwalbe, C.H. (2000)
    A new amidrazone derivative with antimycobacterial activity.
    Acta Cryst.
    C56, e211-e212
  • Rathbone, D.L., Su, D., Wang, Y., and Billington, D.C. (2000)
    Molecular Recognition by Fluorescent Imprinted Polymers.
    Tetrahedron Letters
    , 41, 123-126
  • Simpson, J., Rathbone, D.L., and Billington, D.C. (1999)
    New Solid Phase Knoevenagel Catalyst.
    Tetrahedron Letters
    , 40, 7031-7033
  • Coleman, M.D., Rathbone, D.L., Abberley, L., Lambert, P.A. and Billington, D.C. (1999)
    Preliminary In Vitro Toxicological Evaluation Of A Series Of 2-Pyridylcarboxamidrazone Candidate Anti-Tuberculosis Compounds.
    Environ. Tox. Pharmacol.
    , 7, 59-65
  • Billington, D.C., Coleman, M.D., Ibiabuo, J., Lambert, P.A., Rathbone, D.L., and Tims., K.J. (1998)
    Synthesis And Antimycobacterial Activity of some of 2-Heteroarylcarboxamidrazones.
    Drug Des. Discov
    ., 15, 269-275
  • Stevens, M.F.G., Phillip, K.S., Rathbone, D.L., O'Shea, D.M., Queener, S.F., Schwalbe, C.J., and Lambert, P.A. (1997)
    Structural Studies on Bioactive Compounds. 28. Selective Activity of Triazenyl-Substituted Pyrimethamine Derivatives against Pneumocystis carinii Dihydrofolate Reductase.
    J. Med. Chem
    ., 40, 1886-1893
  • Bedford, S.B., Griffin, R.J., Quarterman, C.P., Rathbone, D.L., Slack, J.A., and Stevens, M.F.G. (1996)
    Synthesis of Water-Soluble Prodrugs of the Cytotoxic Agent Combretastatin A4.
    Bioorg. Med. Chem. Lett.
    , 6, 157-160
  • Ross, K.C., Rathbone, D.L., Thomson, W., and Freeman, S.J.J. (1995)
    Use of Bis[2-(Trialkylsilyl)ethyl]N,N-dialkylphosphoramidites for the Synthesis of Phosphate Monoesters.
    Chem. Soc. Perkin Trans 1
    , 421-426
  • Crout, D.H.G., Davies, S., Heath, R.J., Miles, C.O., Rathbone, D.L., Swoboda, B.E.P., and Gravestock, M. (1994)
    Applications of Hydrolytic and Decarboxylative Enzymes in Biotransformations.
    Biocatalysis
    , 9, 1-30
  • Barlow, R.B., Howard, J.A.K., Batsanov, A.S., O'Shea, D.M., and Rathbone, D.L. (1993)
    Structures of N-Benzyl-(4-diphenylacetoxy)piperidines and N-cyclohexylmethyl-(4-diphenylacetoxy)piperidines.
    Acta Crystallographia Section C - Crystal Structure Communications,
    49; Part 8, 1502-1507
  • Crout, D.H.G., Lee, E.R., and Rathbone, D.L. (1990)
    Absolute Configuration of the Product of the Acetolactate Synthase Reaction by a Novel Method of Analysis Using Acetolactate Decarboxylse.
    J. Chem. Soc. Perkin Trans 1
    , 1367-1369
  • Crout, D.H.G., and Rathbone, D.L. (1989)
    Synthesis of 2-Hydroxy-3-oxocarboxylic Esters from the Corresponding , -Unsaturated Esters by a Simple One-Step Procedure.
    Synthesis
    , 40-42
  • Crout, D.H.G., and Rathbone, D.L. (1988)
    Biotransformations with Acetolactate Decarboxylase: Unusual Conversions of Both Substrate Enantiomers into Products of High Optical Purity.
    J. Chem. Soc. Chem. Commun
    , 98-99
  • Drake, A.F., Siligard, G., Crout, D.H.G., and Rathbone, D.L. (1987)
    Applications of Vibrational Infra Red Circular Dichroism to a Biological Problem: Stereochemistry of Proton Exchange in Acetoin (3-Hydroxybutan-2-one) Catalysed by Acetolactate Decarboxylase.
    J. Chem. Soc. Chem. Commun.
    , 1834-1835
  • Crout, D.H.G., and Rathbone, D.L. (1987)
    Catalysis Di-n-butyltin Oxide of a Tertiary Ketol Rearrangement: Synthesis of Intermediates and Analogues of Valine and Isoleucine Biosynthesis.
    J. Chem. Soc. Chem. Commun.,
    290-291
  • Jones, J.H., Rathbone, D.L., and Wyatt, P.B. (1987)
    The Regiospecific Alkylation of Histidine Side Chains.
    Synthesis
    , 1110-1113
  • Colombo, R., Colombo, F., Derome, A.E., Jones, J.H., Rathbone, D.L., and Thomas, D.W. (1985)
    The Differentiation of - and -Derivatised Hisitidines.
    J. Chem. Soc. Perkin Trans., 1
    , 1811-1815

Patents

  • Rathbone, D.L, Slack, J.A., Griffin, R.J., and Quarterman, (1992)
    Substituted Diphenylethylenes and Analogues or Derivatives Thereof.
    C.P. Patent WO92/16486 PCT/GB92/00498
  • Williams, J.G., Houck, D.R., Smith, D.E., Rathbone, D.L., Billington, D.C. and Golding, B.T., Collington, E.W., Kitchen, J. and Rich, N. (1998)
    Tetracyclic Compounds for Enhancing the Biosynthesis of Erythropoietin, Compositions Containing Same, and Method of Use Thereof US Patent Dkt52519-C, filed 29th April 1998
    US patent 5,985,913
  • Billington, D.C., Rathbone, D.L.,� Ryley, S. and Finn, P. (2000)
    Barbituric acids as therapeutic agents
    British patent GB 0013655.6 filed 05 June 2000; US patent application in progress
  • Parker, K.J., Rathbone, D.L., Lambert, P.A., Coleman, M.D., Hilton, A.C., Worthington, A., Billington, D.C., Anti-bacterial Compounds WO/2006/075159 ANTI-BACTERIAL COMPOUNDS

Published Abstracts

  • Rathbone, D.L., Ali, A., Antonaki, P., Cheek, S., Gill, M. and Hassanali, R. (2005)
    Fluorescent polymeric binding mimics of CYP2D6
    British Pharmaceutical Conference, Journal of Pharmacy and Pharmacology, Science Proceedings, September Supplement, S-35
  • Rathbone, D.L., Parker, K.J., Lambert, P.A. and Coleman, M.D. (2005)
    Discovery of a N1-benzylidene-pyridine-4-carboxamidrazone with potent and selective activity against Gram-positive bacteria.
    British Pharmaceutical Conference, Journal of Pharmacy and Pharmacology, Science Proceedings, September Supplement, S-35
  • Gill, K.S., G.S., Schwalbe, C.H., Rathbone, D.L., Jada, S.R., Stanslas, J. and Stevens, M.F.G. (2001)
    Structural properties of andrographolide derivatives with anti-cancer activity.
    British Pharmaceutical Conference, Journal of Pharmacy and Pharmacology, Science Proceedings, September Supplement, S-36
  • Bajwa, G.S., Schwalbe, C.H. and Rathbone, D.L. (2001)
    Measured and calculated UV spectra for antimicrobial carboxamidrazones.
    British Pharmaceutical Conference 2001 Abstract Book
    : 231
  • Caddick, J., Schwalbe, C.H. and Rathbone, D.L. (2001)
    Quantitative structure-activity calculations for antimalarial compounds related to artimisinin.
    British Pharmaceutical Conference 2001 Abstract Book:
    232
  • Rathbone, D.L., Tims, K.J., Attkins, N., Cann, S.W. and Billington, D.C., (2000)
    QSAR Studies On A Large Set Of Antimycobacterial N1-Benzylidene-heteroarylcarboxamidrazones.
    J.Pharm. Pharmacol
    , 52, supplement , 97
  • Coleman, M.D., Rathbone, D.L., Tims, K.J., Chima, R., Hovey,M.C., Endersby, C., Abberley, L. and Billington, D.C., (2000)
    Predictive Toxicity Studies On A Set Of Antimycobacterial N1Benzylidene-heteroarylcarboxamidrazones.
    J.Pharm. Pharmacol
    , 52, supplement, 292.
  • Rathbone, D.L., Billington, D.C. and Hartell, N.A. (2000)
    Selective Recognition Of cGMP Using A Polymer-Based Fluorescent Chemosensor, Thanh, N.T.K.
    J.Pharm. Pharmacol
    , 52, supplement, 77.
  • Tims, K.J., Rathbone, D.L., Lambert, P.A. and Billington, D.C. (2000)
    Mycobacterium fortuitum as a screening model for Mycobacterium tuberculosis.
    J.Pharm. Pharmacol
    , 52, supplement, 135.
  • Schwalbe, C.H., Rathbone, D.L., Tims, Billington, D.C., Sandbhor, U. and Padhye, S. (2000)
    Effects Of Functional Group Deletion On Structural Features And Antimycobacterial Activity In Pyridylcarboxamidrazones.
    J.Pharm. Pharmacol
    , 52, supplement, 105.
  • Rathbone, D.L., Su, D., Wang, Y-F, and Billington, D.C. (1999)
    Soluble Prodrugs Of The Anticancer Drugs Temozolomide And Mitozolomide.
    J.Pharm. Pharmacol,
    51, supplement, 26.
  • Rathbone, D.L, (1999)
    Solution Phase Polymer-Supported Synthesis Of Potential Antimycobacterial Fatty Acid Analogues.
    J.Pharm. Pharmacol
    , supplement, 51, 219.
  • Howard, S., Rathbone, D.L., O'Carroll B. and Fraser, W. (1999)
    Parallel Matrix Synthesis Of Modified Cytosine And Adenosine Nucleosides.
    J.Pharm. Pharmacol
    , 51, supplement , 201.
  • Simpson, J., Rathbone, D.L., and Billington, D.C. (1999)
    New Solid-Phase Knoevenagel Catalyst For The Synthesis Of Known Anticancer Agents.
    J.Pharm. Pharmacol
    ., 51, supplement , 28.
  • Schwalbe, C.H., Gallagher, C., Lowe, P.R., Billington, D.C., Rathbone, D.L. and Tims, K.J., (1999)
    Comparison Of Structural Features And Antimycobacterial Activity In Isomeric Pyridyl-Carboxamidrazones.
    J.Pharm. Pharmacol
    , 51, supplement , 262
  • Coleman, M.D., Endersby, C., Hovey, M.C., Rathbone, D.L., Billington, D.C. and Tims, K.J., (1999)
    In Vitro Toxicity Evaluation Of Two Novel Anti-Tubercular 2-Pyridyl-Heteroalkylcarboxamidrazone Derivatives.
    J.Pharm. Pharmacol
    , 51, supplement , 243.
  • Simpson, J., Coleman, M.D., Rathbone D.L., and Billington, D.C., (1999)
    Direct Toxicity Of Anti-Cancer Agents.
    J.Pharm. Pharmacol
    , 51, supplement, 130.
  • Billington, D.C., Tims, K J. and Rathbone, D.L. (1998)
    Automated Synthesis And Antimycobacterial Activity Of A Series Of 2-Heteroarylcarbox amidrazones And Related Compounds.
    J. Pharm. Pharmacol
    , 50, supplement, 262
  • Billington, D.C., Hussey, H.J., Rathbone, D.L., Simpson J. and Tisdale M.J. (1998)
    Automated Synthesis Of Anti-Cancer Compounds.
    J. Pharm. Pharmacol.
    , 50, supplement, 108
  • Rathbone, D.L., O'Carroll, B., Wallis, M.P., Farrow, K.C., Mahmood, N., Schwalbe, C.H. and Fraser, W. (1998)
    Isomorphous Nucleosides With Differing Anti-HIV Activities.
    J. Pharm. Pharmacol.
    , 50, supplement, 130
  • Billington, D.C., Coleman, M.D., Rathbone, D.L., Simpson, J., Sowah, L. and Tisdale M.J. (1998)
    Toxicity And Biotransformation Of The Anti-Cancer Agent 7-Methoxy-4-Bromomethyl coumarin.
    J. Pharm. Pharmacol.
    , 50, supplement, 260
  • Schwalbe, C.H., Lowe, P.R., Gordon, B., Rathbone, D.L. and Billington, D.C. (1998)
    Relationship Of Structural And Electronic Properties To Antimycobacterial Activity Of A Series Of 2-Heteroarylcarboxamidrazones.
    J. Pharm. Pharmacol
    ., 50, supplement, 245
  • Billington, D.C., Coleman, M.D., Ibiabuo, J., Lambert, P.A., Rathbone, D.L., and Tims., K.J. (1997)
    Automated Synthesis And Antimycobacterial Activity Of A Series Of 2-Pyridylarylcarboxy amidrazones.
    J. Pharm. Pharmacol
    ., 1997, 49, supplement 4, 8.
  • Billington, D.C., Coleman, M.D., Ibiabuo, J., Lambert, P.A., Rathbone, D.L., and Tims. (1997)
    Automated Synthesis And Antimycobacterial Activity Of A Series Of 2-Heteroarylcarboxy amidrazones, K.J.
    J. Pharm. Pharmacol.,
    49, supplement 4, 66.

Employable Graduates; Exploitable Research